

## Mentors Biography

### PhD Career Pathway Workshop 2021

	<p><b>Professor David Goldstein</b></p> <p>Professor David Goldstein is the Director of the TCRN at UNSW. David brings together expertise across cancer research and clinical practice domains, delivering infrastructure and research enablers to support the clinical, educational and research endeavours of TCRN members and partners. David is a conjoint clinical professor at the Prince of Wales Clinical School, UNSW and a senior staff specialist in the Department of Medical Oncology at the Prince of Wales Hospital, Randwick. His research is focused on novel therapeutics trials and clinical research into pancreatic cancer, gastrointestinal stromal tumours and renal cell carcinoma; and on the psychosocial aspects of cancer care.</p> <p>David was the treasurer of the AGITG until 2016, was the president of COSA (2006-2008) and on the first executive board of COSA (2013-2015) and was a founding member of the NSW Pancreatic Cancer Network. He is also the recipient of the Gold Maryalyan Award for services to COSA, the Vietnam Peoples Health Medal for contributions to improving cancer services to in Hue, Vietnam and the make a difference award for pancreatic cancer from the CINSW.</p>
<p><b>Academia</b></p>	
	<p><b>Professor Maria Kavallaris AM</b></p> <p>Professor Maria Kavallaris AM is Founding Director of the Australian Centre for NanoMedicine at the University of New South Wales, Head of Translational Cancer NanoMedicine Theme and Executive Head, Research Engagement at the Children’s Cancer Institute. Maria is a National Health and Medical Research Council (NHMRC) Principal Research Fellow and is recognised for her innovation in driving multidisciplinary research in cancer nanomedicine. An outstanding scientific leader, she is internationally recognised for her research in cancer biology and therapeutics. Her research has identified clinically important mechanisms of resistance to cancer therapies, with her discoveries leading to patents, industry and clinical linkages for the development of cancer therapeutics and devices. Maria’s pioneering research has shown effective nanoparticle-based delivery of gene silencing material and chemotherapy, can reduce tumour growth in aggressive cancers.</p> <p>Maria is Chair of the Australian Institute for Policy and Science, and a Life Member and past-President of the Australian Society for Medical Research. The impact of her research has been recognised many times, including via receipt of the Australian Museum Eureka Prize, as well as being named by the NHMRC as an Australian ‘high achiever’ in health and medical research. Recognition of her significant contributions to innovation is reflected in her being named in 2015 amongst the AFR/Westpac <i>100 Women of Influence</i> (Innovation category), as well as the inaugural <i>Knowledge Nation 100</i> – the ‘rock stars’ of Australia’s innovation-driven new economy, and received the 2017 Premiers Science and Engineering Award for Leadership in Innovation in NSW. The Australian Society for Biochemistry and Molecular Biology awarded Maria the 2019 Lemberg Medal that recognises distinguished biochemists or molecular biologists, that have made significant contributions to the scientific community. In recognition of outstanding contributions, Maria was selected as the 2020 Premier’s NSW Woman of the Year. A recognised medical research leader, she has been appointed on government funding panels including NHMRC and the Medical Research Future Fund, where she contributes to high level policy. She is a Fellow of the Australian Academy of Health and Medical Sciences and a Fellow of the Royal Society of NSW. In 2019, Maria was appointed a Member (AM) of the <i>Order of Australia</i> for her significant service to medicine, and to medical research, in the field of childhood and adult cancers.</p>

	<p><b>Professor Mary Bebawy</b></p> <p>Professor Mary Bebawy has a PhD in Pharmacy (USYD) and is the Head of the Laboratory of Cancer Cell Biology and Therapeutics, Graduate School of Health UTS. She has an active research portfolio focusing on the molecular basis of cancer relapse. She is an internationally recognized cancer researcher and pharmaceutical scientist with a background in commercial R &amp; D. Her team were the first to discover the role of extracellular vesicles (EVs) in the spread of cancer multidrug resistance (MDR) (Bebawy et al., 2009). Since this discovery, A/Prof Bebawy and her team were the first to also discover that EVs can re-template the proteome and transcriptome of cancer cells to ensure the transfer and dominance of cancer traits within cell populations (Jaswail et al., 2012; Lu et al., 2013; Pokharel et al., 2014; Gong et al., 2013; 2014). These findings have since been translated clinically with her team discovering the utility of EVs as a prognostic in Myeloma (Krishnan et al., 2016).</p>
	<p><b>Associate Professor Natalie Taylor</b></p> <p>Associate Professor Natalie Taylor is a health psychologist and implementation scientist with expertise in health and organisational behaviour change. Based in the Cancer Research Division at Cancer Council New South Wales, her research currently focusses on the impact and cost-effectiveness of behaviour change and implementation science approaches on the translation of evidence into clinical practice to improve healthcare delivery and outcomes for patients.</p> <p>Leading a research team of eight, including post-doctoral researchers and PhD students, Natalie's current program of work is funded by a Cancer Australia Project Grant and a Cancer Institute NSW Career Development Fellowship. She is also a chief investigator to an Australian Genomics Health Alliance project focusing on the implementation of genomics across Australia, and a multi-state NHMRC Partnership Project Grant.</p>
<p><b>Clinician research</b></p>	
	<p><b>Professor Meera Agar</b></p> <p>Professor Meera Agar is a palliative medicine physician, with a particular interest in the supportive care needs of people suffering from advanced illness on the brain. Meera leads a clinical research portfolio at UTS, including clinical trials and health service evaluation. She led a world-first clinical trial of antipsychotics in delirium and is leading a NSW Government-funded trial of the use of medicinal cannabis for the terminally ill. A Fellow of the Royal Australasian College of Physicians, Fellow of the Australasian Chapter of Palliative Medicine and clinician scientist, she holds a Master in Palliative Care. Her doctorate was awarded in the area of delirium in advanced illness.</p>
<p><b>Industry</b></p>	
	<p><b>Dr Kevin Lynch</b></p> <p>An Australian trained physician, Kevin Lynch joined the Pharmaceutical Industry in 1993, continuing studies in Pharmaceutical Medicine. He gained his Membership of the Faculty of Pharmaceutical Medicine in 1998 by thesis and was awarded Faculty Fellowship in 2004.</p> <p>During 28 years in Clinical Development and Medical Affairs, he has managed all aspects of drug development, including many Phase I through to Phase III and post-registration studies, as well as establishing departments responsible for Drug Safety, Medical Communications and Medical Affairs. He was Oncology Medical Director for Novartis</p>



Australia and New Zealand, with developmental responsibility for multiple breakthrough cancer treatments, including Glivec, Tasigna, Exjade, Zometa, Femara, and Sandostatin.

In 2008 he joined Celgene Pty Ltd as Medical Director for Australia and New Zealand, and then as Director, Clinical Development and Medical Affairs, Asia-Pacific. In 2011 he moved to Switzerland as Vice President and head of Clinical Research and Development for Europe, before returning to Asia-Pacific as Vice President, Clinical Development and Medical Affairs until late in 2019. With Celgene, Kevin worked successfully on the development and registration of drugs such as Revlimid, Vidaza, Pomalyst, Abraxane and Reblozyl. After a year of consulting to several Biotech and Pharma companies, Kevin has recently started in a new role as Chief Medical Officer of Antengene Corp, a US-Chinese-Australian Biotech committed to haematology/oncology research and drug development. Kevin is co-author on more than 100 publications and abstracts at international meetings.



### **Dr Orin Chisholm**

Orin Chisholm, BSc (Hons), GCULT, PhD, SFHEA.

Orin is a regulatory consultant providing services to biopharmaceutical companies bringing innovative new medicines to market. She has adjunct appointments with UNSW Sydney, Australia and Arizona State University, USA. Orin is on the Board of ARCS Australia which provides education and professional development to employees in the pharmaceuticals and medical technology sector in Australia. She is also on the editorial board of RAPS and a reviewer for Therapeutic Innovation and Regulatory Affairs and Frontiers in Pharmacology and Medical Technology. She was previously a member of the Gene Technology Technical Advisory Committee in Australia, providing advice to the Australian Gene Technology Regulator on matters relating to the regulation of gene technology. Orin has worked in regulatory affairs roles within several pharmaceutical companies since 2000, with a particular focus on the registration of oncology and rare disease products. She is passionate about skills development and education in regulatory affairs and pharmaceutical medicine and was the program director for the Master of Pharmaceutical Medicine program at UNSW Sydney for 8 years. Orin received the TOPRA award for regulatory education excellence in 2017 and was made a Senior Fellow of the Higher Education Academy (UK) in 2018 in recognition of her expertise in regulatory education.




### **Dr Louise Young**

Dr Louise Young is a Senior Medical Affairs Manager at the pharmaceutical company Eisai Australia Pty Ltd and is responsible for ANZ Medical Affairs within the Oncology Division, working within multiple solid tumour streams. Louise has worked within the Life Sciences arena in Australia both in academia and industry for the last ten years after completing a PhD in Immunology at The Walter and Eliza Hall Institute of Medical Research.

### **Dr Qiao Qiao (Early Career)**

Qiao is an entrepreneurial life science business development professional. He is part of the Life Sciences team in Knowledge Exchange (KE). He also works closely with the UNSW Torch team and travels frequently to China to explore partnership opportunity. Qiao is dedicated to building long-lasting high value cooperation with biotechnology and pharmaceutical companies, sophisticated equity investors and other external partners. He has experience in a broad field, such as cancer, virology, biochemistry, stem



cell biology. Prior to joining KE, Qiao worked at NewSouth Innovations (NSi), UNSW Torch (Life Sciences) as well as at Bio-Link Australia, a boutique life sciences consulting company. Qiao completed his PhD (Medicine) at UNSW and was awarded BSc (Biotech) with first class honours from the University of Adelaide.

**Government**



**Dr Cleola Anderiesz**

Dr Cleola Anderiesz is the Deputy Chief Executive Officer at Cancer Australia. Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care. A research scientist by training, Cleola has a PhD in Medicine and is currently completing her Senior Executive MBA. She has worked in Australia and abroad in laboratory and clinical research and has worked in cancer control for the last seventeen years, joining Cancer Australia upon its establishment in 2006. Working in both the not-for-profit and the public sector she has been involved in policy development, national program design, implementation and evaluation.



**Dr Paul Jackson**

Dr Paul Jackson is Head of National Research and Data at Cancer Australia. In this role, Paul provides leadership and oversight of the agency’s significant programs in research, including the priority-driven collaborative cancer research scheme (PdCCRS), clinical trials, evidence translation and national data. More recently Paul’s responsibilities have included providing oversight of Cancer Australia’s implementation of the Australian Brain Cancer Mission and the Investing in Medical Research - Fighting Childhood Cancer Measure, leading the evidence building component of the Lung Cancer Screening enquiry being undertaken by Cancer Australia, and providing strategic input into the agency’s responses to the COVID-19 pandemic

His experience and expertise in leading national collaborative cancer research funding programs is recognized through current appointments as Chair of the International Cancer Research Partnership (ICRP), Cancer Australia’s representative on the Government’s Blood Cancers Taskforce and The Prostate Cancer Research Alliance, and member of the Scientific Steering Group for the Genomics Cancer Clinical Trials Initiative. Dr Paul Jackson joined Cancer Australia as member of the Research and Clinical Trials team in 2007, to lead development and implementation of the agency’s innovative Priority-driven Collaborative Cancer Research Scheme (PdCCRS). Dr Jackson’s background is as a cancer researcher with an interest in urological cancers. He joined Cancer Australia from his position as Principal Scientific Officer and Conjoint A/Professor at the Oncology Research Centre, Prince of Wales Hospital in Sydney. Dr Jackson was awarded his PhD from the Australian National University (ANU) in 1987 and his 20-year career in cancer research also included research appointments in the Department of Biochemistry at the University of Leicester and John Curtin School of Medical Research at the ANU.

## RESOURCES

For more skills and training info [www.tcrn@unsw.edu.au](mailto:www.tcrn@unsw.edu.au)

### For grants and fellowships:

**GMO:** Your University Grans Management Office (GMO)

**SPIN:** <http://infoedglobal.com/solutions/grants-contracts/spin-funding-opportunities/>

**ASMR Mentoring program:** <https://asmr.org.au/mentoring-program/>

[www.nhmrc.gov.au/](http://www.nhmrc.gov.au/)

NHMRC funding supports research across the full spectrum of health and medical research, from basic science through to clinical, public health and health services research

**GrantConnect@finance.gov.au**

### Career development

<a href="http://APJOBS.GOV.AU">APJOBS.GOV.AU</a>	Career in Australian Public Service (APS)
<a href="http://CAREERS.ABPI.CO.UK">CAREERS.ABPI.CO.UK</a>	Pharmaceutical Industry Career information from the ABPI (The Association of the British Pharmaceutical Industry), the trade body of the UK pharmaceutical industry.
<a href="http://myidp.sciencecareers.org">myidp.sciencecareers.org</a>	The Individual Development Plan (IDP) concept is commonly used in industry to help employees define and pursue their career goals. In 2003, the Federation of American Societies for Experimental Biology (FASEB) proposed an IDP framework for postdoctoral fellows in the sciences. Expanding on that framework, myIDP is a unique, web-based career-planning tool tailored to meet the needs of PhD students and postdocs in the sciences
<a href="http://www.sciencemag.org/careers">www.sciencemag.org/careers</a>	AAAS Science Career Trends and opportunities.
<a href="http://www.nature.com/naturejobs/career-toolkit/index.html">www.nature.com/naturejobs/career-toolkit/index.html</a>	Nature Jobs Career Toolkit
<b>10 Career Paths for PhDs - Jobs.ac.uk</b>	<a href="https://www.jobs.ac.uk/media/pdf/careers/resources/10-career-paths-for-phds.pdf">https://www.jobs.ac.uk/media/pdf/careers/resources/10-career-paths-for-phds.pdf</a>
<a href="https://www.arcs.com.au/partnerships/criteria-program">https://www.arcs.com.au/partnerships/criteria-program</a>	CRITERIA Program - Internship and job listing